Stock Market Reviews

Read and share opinions on PLRZ (Polyrizon Ltd.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation
  Nov 6, 2025
• Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy
  Oct 6, 2025
• Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker
  Sep 19, 2025
• Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study
  Sep 12, 2025
• Polyrizon Regains Compliance with Nasdaq Listing Requirements
  Aug 14, 2025
• Polyrizon Retains Nasdaq Listing Following Hearings Panel
  Jul 15, 2025
• Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics
  Jun 12, 2025
• Polyrizon Announces Receipt of Nasdaq Delisting Notice
  May 23, 2025
• Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform
  May 21, 2025
• Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment
  May 13, 2025
• Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model
  Apr 25, 2025
• Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements
  Apr 11, 2025
• Polyrizon Engages Leading Branding Firm for Strategic Brand Development
  Apr 2, 2025
• Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement
  Apr 1, 2025
• Polyrizon Ltd. Announces $17.0 Million Private Placement
  Mar 31, 2025
• Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting
  Mar 27, 2025
• Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment
  Mar 25, 2025